Product Information
Registration Status: ActiveSIN09542P
ULTIVA FOR INJECTION 1mg/VIAL is approved to be sold in Singapore with effective from 1997-11-21. It is marketed by DCH AURIGA SINGAPORE, with the registration number of SIN09542P.
This product contains Remifentanil 1mg/vial in the form of INJECTION, POWDER, FOR SOLUTION. It is approved for INTRAVENOUS use.
This product is manufactured by GlaxoSmithKline Manufacturing S.p.A. in ITALY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist. Hence, it causes a reduction in sympathetic nervous system tone, respiratory depression and analgesia.
Indication
For use during the induction and maintenance of general anesthesia.
Mechanism of Action
Remifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.
Clearance
* 40 mL/min/kg [young, healthy adults]
Active Ingredient/Synonyms
REMIFENTANIL | Remifentanyl | Remifentanil |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.